Business Description
Rocket Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US77313F1066
Description
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.36 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.4 | |||||
| 3-Year EPS without NRI Growth Rate | -27.3 | |||||
| 3-Year FCF Growth Rate | -15.2 | |||||
| 3-Year Book Growth Rate | 3.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.87 | |||||
| 9-Day RSI | 68.49 | |||||
| 14-Day RSI | 67.95 | |||||
| 6-1 Month Momentum % | -16.58 | |||||
| 12-1 Month Momentum % | 5.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.35 | |||||
| Quick Ratio | 13.35 | |||||
| Cash Ratio | 13.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13 | |||||
| Shareholder Yield % | -41.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -55.9 | |||||
| ROA % | -49.65 | |||||
| ROIC % | -161.78 | |||||
| ROC (Joel Greenblatt) % | -314.17 | |||||
| ROCE % | -53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.17 | |||||
| Price-to-Tangible-Book | 4.73 | |||||
| EV-to-EBIT | -7.41 | |||||
| EV-to-Forward-EBIT | -20.3 | |||||
| EV-to-EBITDA | -7.62 | |||||
| EV-to-Forward-EBITDA | -20.95 | |||||
| EV-to-Forward-Revenue | 11.47 | |||||
| EV-to-FCF | -7.87 | |||||
| Price-to-Net-Current-Asset-Value | 5.79 | |||||
| Price-to-Net-Cash | 5.95 | |||||
| Earnings Yield (Greenblatt) % | -13.5 | |||||
| FCF Yield % | -10.49 |
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RCKT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rocket Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.19 | ||
| Beta | 0.76 | ||
| Volatility % | 55.33 | ||
| 14-Day RSI | 67.95 | ||
| 14-Day ATR ($) | 1.185697 | ||
| 20-Day SMA ($) | 22.777 | ||
| 12-1 Month Momentum % | 5.22 | ||
| 52-Week Range ($) | 14.89 - 26.61 | ||
| Shares Outstanding (Mil) | 90.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rocket Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rocket Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rocket Pharmaceuticals Inc Frequently Asked Questions
What is Rocket Pharmaceuticals Inc(RCKT)'s stock price today?
The current price of RCKT is $25.03. The 52 week high of RCKT is $26.61 and 52 week low is $14.89.
When is next earnings date of Rocket Pharmaceuticals Inc(RCKT)?
The next earnings date of Rocket Pharmaceuticals Inc(RCKT) is 2024-02-27 Est..
Does Rocket Pharmaceuticals Inc(RCKT) pay dividends? If so, how much?
Rocket Pharmaceuticals Inc(RCKT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers